Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Study sponsor: CytoDyn, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-11-07Actual
Enrollment · participants16Actual
Source updated2026-01-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.